Add to ORKGThe recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has been lauded as a success story for personalized cancer therapy since short-term clinical responses were observed in the majority patients. However, initial responses were followed by subsequent tumor re-growth and a subset of patients showed intrinsic resistance. Bi-directional translational efforts are now essential to determine the mechanisms underlying acquired/secondary and intrinsic resistance to RAF inhibitors
SummaryBRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhib...
The development of acquired drug resistance hampers the long-term success of B-RAF inhibitor therapy...
The development of acquired drug resistance hampers the long-term success of B-RAF inhibitor therapy...
The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has ...
The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has ...
The identification of BRAF V600E as a driving mutation in approximately 50% of melanoma and the subs...
In early 2011, we reviewed the initial success of the RAF inhibitor, vemurafenib, in mutant V600 BRA...
In early 2011, we reviewed the initial success of the RAF inhibitor vemurafenib in mutant V600 BRAF ...
Over the past decade, immune checkpoint inhibitors (ICI) have revolutionized the treatment of advanc...
Summary: ATP-competitive RAF inhibitors elicit profound but often temporary antitumor responses in ...
Melanoma cells driven by mutant v-raf murine sarcoma viral oncogene homolog B1 (B-RAF) are highly re...
The discovery of activating mutations in BRAF at high frequency in cutaneous melanoma opened the doo...
Hyperactive RAS/RAF/MEK/ERK signaling has a well-defined role in cancer biology. Targeting this path...
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mut...
Treatment of BRAF‐mutant melanomas with MAP kinase pathway inhibitors is paradigmatic of the promise...
SummaryBRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhib...
The development of acquired drug resistance hampers the long-term success of B-RAF inhibitor therapy...
The development of acquired drug resistance hampers the long-term success of B-RAF inhibitor therapy...
The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has ...
The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has ...
The identification of BRAF V600E as a driving mutation in approximately 50% of melanoma and the subs...
In early 2011, we reviewed the initial success of the RAF inhibitor, vemurafenib, in mutant V600 BRA...
In early 2011, we reviewed the initial success of the RAF inhibitor vemurafenib in mutant V600 BRAF ...
Over the past decade, immune checkpoint inhibitors (ICI) have revolutionized the treatment of advanc...
Summary: ATP-competitive RAF inhibitors elicit profound but often temporary antitumor responses in ...
Melanoma cells driven by mutant v-raf murine sarcoma viral oncogene homolog B1 (B-RAF) are highly re...
The discovery of activating mutations in BRAF at high frequency in cutaneous melanoma opened the doo...
Hyperactive RAS/RAF/MEK/ERK signaling has a well-defined role in cancer biology. Targeting this path...
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mut...
Treatment of BRAF‐mutant melanomas with MAP kinase pathway inhibitors is paradigmatic of the promise...
SummaryBRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhib...
The development of acquired drug resistance hampers the long-term success of B-RAF inhibitor therapy...
The development of acquired drug resistance hampers the long-term success of B-RAF inhibitor therapy...